Brivudin

Author:Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 01.06.2022

Dieser Artikel auf Deutsch

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

Substance from the group of virustatics.

Half-lifeThis section has been translated automatically.

12–15 h

IndicationThis section has been translated automatically.

Infections with varicella zoster in immunocompetent adults. Efficacy in children has not been proven.

Limited indicationThis section has been translated automatically.

Restricted kidney function, pregnancy, lactation.

Dosage and method of useThis section has been translated automatically.

Adults: 125 mg p.o. once/day for 7 days.

Undesirable effectsThis section has been translated automatically.

Nausea, vomiting, diarrhoea, abdominal pain, headache, dizziness, proteinuria, glucosuria, creatinine and transaminase increase, leukopenia and thrombopenia, loss of appetite.

InteractionsThis section has been translated automatically.

Increase in toxicity of fluorouracil and tegafur. Also no application of 5-FU topically (e.g. for the treatment of actinic keratosis).

ContraindicationThis section has been translated automatically.

Patients with cytostatic therapy and antifungal therapy with flucytosine, also with topical application). The interaction with 5-fluoropyrimidines can be fatal!!!

PreparationsThis section has been translated automatically.

Zostex

Note(s)This section has been translated automatically.

The rate of post-zosteric neuralgia should be reduced by the active substance.

LiteratureThis section has been translated automatically.

  1. Dworkin RH et al (2007) Recommendations for the management of herpes zoster. Clin Infect Dis 44: 1-26
  2. Drug Commission of the German Medical Association: (2006) "UAW - learning from mistakes": potentially fatal interaction between brivudine (Zostex®) and 5-fluoropyrimidines. Dtsch Arztebl 103: A 1922-1923
  3. WHO Pharmaceuticals Newsletter (2018) Brivudine and 5-fluorouracil - Persistence of a fatal drug-drug interaction. WHO Pharmaceuticals Newsletter 6: 20-24
  4. https://www.akdae.de/Arzneimittelsicherheit/DSM/Archiv/2019-11.html
  5. https://www.aerzteblatt-sachsen-anhalt.de/ausgabe/arzneimittelkommission/3103-rote-hand-brief-zu-brivudin-potenziell-toedliche-toxizitaet-von-fluoropyrimidinen-bei-der-anwendung-kurz-vor-gleichzeitig-mit-oder-innerhalb-von-vier-wochen-nach-ende-der-behandlung-mit-brivudin.html

Authors

Last updated on: 01.06.2022

Author: Prof. Dr. med. Peter Altmeyer